Enovis Co. (NYSE:ENOV) Stock Holdings Lessened by Magnetar Financial LLC

Magnetar Financial LLC decreased its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 33.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 737,655 shares of the company's stock after selling 362,949 shares during the period. Magnetar Financial LLC owned about 1.30% of Enovis worth $32,368,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. UMB Bank n.a. grew its position in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after acquiring an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. grew its position in Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after purchasing an additional 300 shares during the last quarter. FMR LLC increased its stake in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after purchasing an additional 484 shares during the period. XTX Topco Ltd acquired a new position in shares of Enovis during the third quarter worth approximately $217,000. Finally, Legacy Capital Wealth Partners LLC acquired a new position in shares of Enovis during the fourth quarter worth approximately $228,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC lowered their target price on Enovis from $65.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th.

Remove Ads

Enovis Price Performance

Shares of ENOV stock traded up $0.93 during midday trading on Monday, reaching $40.01. 558,415 shares of the company were exchanged, compared to its average volume of 672,455. The company's 50 day moving average price is $42.72 and its two-hundred day moving average price is $43.50. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company has a market cap of $2.28 billion, a P/E ratio of -18.27 and a beta of 2.05. Enovis Co. has a 12 month low of $35.14 and a 12 month high of $62.79.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. On average, sell-side analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.